This study is testing an investigational drug called frexalimab in adolescents and adults age 12-35 years old with newly diagnosed type 1 diabetes who are on insulin therapy (adults age 18-35 will be enrolled first, followed by 12 to 21-year-olds later in the study). You will...
TrialNet is testing rituximab-pvvr and abatacept, one after the other, to learn if using both treatments extend insulin production in people (ages 8-45) who were newly diagnosed with type 1 diabetes (T1D). Each therapy has a history of safety and effectiveness. Rituximab-pvvr is FDA-approved to...
For people age 12 – 35 years who have been diagnosed with type 1 diabetes in the past 3 months, this study tests two JAK inhibitors (abrocitinib and ritlecitinib) to see if either or both can preserve insulin production. TrialNet researchers are testing two different JAK...
[box class="summary"][/box]We are inviting you to participate in a research study to help us improve our understanding of diabetes and immune mediated diseases. The study consists of a computer registry where we store your contact, research, and health information, and a sample repository where we...
[box class="summary"][/box]Pathway to Prevention screening is the first step for all TrialNet prevention studies. Screening is offered at no cost to eligible individuals to evaluate their personal risk of developing the disease. This unique screening can identify the early stages of type 1 diabetes (T1D) years...
